(Q43186384)

15 November 2017

title

Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial (English)

1 reference

multicenter clinical trial

15 November 2017

main subject

1 reference

1 reference

Louis J Aronne

1

1 reference

15 November 2017

Amy E Halseth

2

1 reference

15 November 2017

Colleen M Burns

3

1 reference

15 November 2017

Stephan Miller

4

1 reference

15 November 2017

Larry Z Shen

5

1 reference

15 November 2017

language of work or name

1 reference

21 January 2010

1 reference

15 November 2017

1 reference

15 November 2017

volume

18

1 reference

15 November 2017

issue

9

1 reference

15 November 2017

page(s)

1739-1746

1 reference

The role of patients' expectations and goals in the behavioral and pharmacological treatment of obesity.

15 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.478

Great Expectations: "I'm Losing 25% of My Weight No Matter What You Say"

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.478

Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.478

Effects of weight loss in overweight/obese individuals and long-term lipid outcomes--a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.478

Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.478

A critical review of the cannabinoid receptor as a drug target for obesity management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.478

Anorectics on trial: a half century of federal regulation of prescription appetite suppressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.478

Pharmacological treatment of the overweight patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.478

Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.478

Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.478

Amylinergic control of food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.478

Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.478

The gut and energy balance: visceral allies in the obesity wars

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.478

Role of islet-, gut-, and adipocyte-derived hormones in the central control of food intake and body weight: implications for an integrated neurohormonal approach to obesity pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.478

Central nervous system control of food intake and body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.478

Synergy of sibutramine and low-dose leptin in treatment of diet-induced obesity in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.478

Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.478

A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.478

Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.478

The hospital anxiety and depression scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.478

Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Associati

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.478

Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.478

Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.478

Comparison of continuous and intermittent anorectic therapy in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.478

The efficacy and safety of sibutramine for weight loss: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.478

Long term pharmacotherapy for obesity and overweight: updated meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.478

Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.478

Pharmacotherapy for obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.478

Pharmacotherapy for obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.478

Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2009.478

31 March 2020

Identifiers

DOI

10.1038/OBY.2009.478

1 reference

15 November 2017

1 reference